ReviewEuropean journal of nuclear medicine and molecular imaging2004
[18F]FLT-PET in oncology: current status and opportunities.
Review in European journal of nuclear medicine and molecular imaging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preclinical Applications of 3'-Deoxy-3'-[Theranostics · 2017Pooled it
- [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.Annals of nuclear medicine · 2012Trial
- Dual-tracerRadiology case reports · 2026Article
- Redefining Soft Tissue Sarcoma Imaging: The Expanding Role of Positron Emission Tomography/Computed Tomography: A Review.World journal of nuclear medicine · 2026Review
- Advances in GPCR-Targeted PET Radiotracer Patents (2020-2025).Pharmaceuticals (Basel, Switzerland) · 2026Review
- Non-FDG PET/CT.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine.Cancer medicine · 2025Review
- 18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors.Molecular cancer therapeutics · 2025Article
- Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated byInternational journal of hematology · 2023Article
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.Cancer chemotherapy and pharmacology · 2023Review
- Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model.Cancer biotherapy & radiopharmaceuticals · 2023Article
- PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach.Frontiers in nuclear medicine · 2023Review
- Comparison ofTomography (Ann Arbor, Mich.) · 2022Article
- Potential novel imaging targets of inflammation in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
- 3'-[Journal of translational medicine · 2022Article
- Glucose-Thymidine Ratio as a Metabolism Index UsingInternational journal of molecular sciences · 2022Article
- Direct Cell Radiolabeling forChemical reviews · 2022Review
- Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.Biomedicines · 2022Review
- Differences between [Diagnostics (Basel, Switzerland) · 2021Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this review, the basis of [18F]FLT as a proliferation tracer is discussed. Furthermore, an overview of the current status of [18F]FLT-PET research is given. The results of this research show that although [18F]FLT is a tracer that visualises cellular proliferation, it also has certain limitations. In comparison with the most widely used PET tracer, [18F]FDG, [18F]FLT uptake is lower in most cases. Furthermore, [18F]FLT uptake does not always reflect the tumour cell proliferation rate, for example during or shortly after certain chemotherapy regimens. The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer.
Indexed as
Identifiers
15565331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.